Today's 3 Worst Stocks in the S&P 500
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.
An hour before the opening bell this morning, jobless claims numbers for last week hit the Street. They showed claims falling from 351,000 to 331,000 for the week ending February 1. An hour later, the stock market did something it hadn't done much of this year: it rallied. In fact, the S&P 500 Index went on to post its best day of 2014, surging 21 points, or 1.2%, to end at 1,773.
Of course, no matter how healthy the tree is, there are always a few bad apples. Chesapeake Energy stock was just such an apple on Thursday, as shares tumbled 6.9% following an anemic 2014 outlook. Chesapeake Energy is, from an outside perspective, in an enviable position, being one of the top producers of natural gas in the U.S. But the domestic energy revolution is facing a setback this winter, as unusually harsh weather has hampered production at precisely the time when natural gas prices are spiking to highs not seen in the last five years. In other words, this is exactly the wrong time for production to start slumping.
Another energy company, Tesoro , also slipped big time today, losing 4.7%, as the refiner reported underwhelming earnings. Now, when I say "underwhelming," I really mean "horrendous." Analysts were calling for earnings per share of $0.31. Tesoro instead earned a measly $0.04 per share. The main culprit was dramatically reduced margins, which cratered more than 60% for fuel sales. Tesoro, which both refines oil and sells fuel at company-operated gas stations, was briefly and bizarrely forced by market conditions in California to buy fuel at high prices and then sell it for a loss. Not surprisingly, this business model produced disappointing results.
Lastly, California-based biotech Gilead Sciences fell 2.1% Thursday, ending as one of the S&P's worst performers for a second straight day. Interestingly, Gilead Sciences actually reported blowout earnings late Tuesday, but shares have since sold off. That's because the stock market's all about expectations, and one of Wall Street's aspirations for Gilead is the success of its Hepatitis-C treatment Sovaldi. When the company failed to include Sovaldi sales projections in its outlook for the coming year, some shareholders got antsy and decided not to bet on the drug's success.
Three stocks for America's next energy boom
Record oil and natural gas production is revolutionizing the United States' energy position. Winter's unfavorable weather should only be a seasonal setback; America's long-term production outlook looks better than ever. Finding the right plays, while historic amounts of capital expenditures are flooding the industry, will pad your investment nest egg. For this reason, the Motley Fool is offering a comprehensive look at three energy companies set to soar during this transformation in the energy industry. To find out which three companies are spreading their wings, check out the special free report, "3 Stocks for the American Energy Bonanza." Don't miss out on this timely opportunity; click here to access your report -- it's absolutely free.
The article Today's 3 Worst Stocks in the S&P 500 originally appeared on Fool.com.John Divine has no position in any stocks mentioned. You can follow him on Twitter @divinebizkid and on Motley Fool CAPS @TMFDivine.The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.